Match!
C Georgiadis
UCL Institute of Child Health
Genetic enhancementGenome editingCancer researchMedicineBiology
18Publications
4H-index
56Citations
What is this?
Publications 20
Newest
#1Roland PreeceH-Index: 2
#2C GeorgiadisH-Index: 4
Last. Waseem Qasim (GOSH: Great Ormond Street Hospital)H-Index: 28
view all 6 authors...
RNA polymerase III (Pol III) promoters express short non-coding RNAs and have been adopted for expression of microRNA, interference RNA, and CRISPR single guide RNA (sgRNA). Vectors incorporating H1 and U6 Pol III promoters are being applied for therapeutic genome editing, including multiplexed CRISPR/Cas9 effects. We report a nucleosome-depleted, minimal U6 promoter, which when embedded within lentiviral long terminal repeat (LTR) regions, supports high level transcriptional activity. Furthermo...
Source
#1A PetrovaH-Index: 5
#2C GeorgiadisH-Index: 4
Last. Waseem QasimH-Index: 28
view all 8 authors...
Recessive dystrophic epidermolysis bullosa (RDEB) is a debilitating genodermatosis caused by loss-of-function mutations in COL7A1 encoding type VII collagen (C7), the main component of anchoring fibrils at the dermal–epidermal junction. With no curative treatments presently available, retrovirally transduced autologous epidermal grafts and intradermal lentivirally engineered fibroblast injections are being investigated. Alternative approaches aim to infuse allogeneic mesenchymal stromal cells (M...
Source
#1C GeorgiadisH-Index: 4
#2Jane RasaiyaahH-Index: 13
Last. Waseem Qasim (GOSH: Great Ormond Street Hospital)H-Index: 28
view all 7 authors...
Source
#1Su M. LwinH-Index: 6
#2Farhatullah SyedH-Index: 2
Last. John MuzicH-Index: 64
view all 41 authors...
5 CitationsSource
#1Roland PreeceH-Index: 2
#2C GeorgiadisH-Index: 4
Gene editing tools are being rapidly developed, accelerating many areas of cell and gene therapy research. Each successive gene editing technology promises increased efficacy, improved specificity, reduced manufacturing cost and design complexity; all of which are currently epitomised by the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas9) platform. Since its conceptualisation, CRISPR-based gene editing has been applied to existing methodolo...
1 CitationsSource
#1Jane RasaiyaahH-Index: 1
#2C GeorgiadisH-Index: 4
Last. Waseem QasimH-Index: 28
view all 5 authors...
4 CitationsSource
#1C GeorgiadisH-Index: 4
#2Roland PreeceH-Index: 2
Last. Waseem Qasim (GOSH: Great Ormond Street Hospital)H-Index: 28
view all 12 authors...
Gene editing can be used to overcome allo-recognition, which otherwise limits allogeneic T cell therapies. Initial proof-of-concept applications have included generation of such "universal" T cells expressing chimeric antigen receptors (CARs) against CD19 target antigens combined with transient expression of DNA-targeting nucleases to disrupt the T cell receptor alpha constant chain (TRAC). Although relatively efficient, transgene expression and editing effects were unlinked, yields variable, an...
16 CitationsSource
AbstractThe first applications of gene-edited T cells are reaching clinical phase testing as new reagents including TALENs and CRISPR/Cas9 nucleases have emerged to allow efficient and highly specific cell engineering. The transplant setting is an ideal testing ground for these new therapies, given the established infrastructure for cell based interventions. Powerful new immunotherapies are anticipated, which will need to be evaluated in carefully monitored studies, designed to capture both mole...
8 CitationsSource
#1C GeorgiadisH-Index: 4
#2Roland PreeceH-Index: 2
Last. Waseem QasimH-Index: 28
view all 4 authors...
#1C Georgiadis (ICH: UCL Institute of Child Health)H-Index: 4
#2Farhatullah Syed (ICH: UCL Institute of Child Health)H-Index: 14
Last. Waseem Qasim (ICH: UCL Institute of Child Health)H-Index: 28
view all 16 authors...
Cells therapies, engineered to secrete replacement proteins, are being developed to ameliorate otherwise debilitating diseases. Recessive dystrophic epidermolysis bullosa (RDEB) is caused by defects of type VII collagen, a protein essential for anchoring fibril formation at the dermal-epidermal junction. Whereas allogeneic fibroblasts injected directly into the dermis can mediate transient disease modulation, autologous gene-modified fibroblasts should evade immunological rejection and support s...
25 CitationsSource
12